<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143753</url>
  </required_header>
  <id_info>
    <org_study_id>NP25247</org_study_id>
    <secondary_id>2010-018330-42</secondary_id>
    <nct_id>NCT01143753</nct_id>
  </id_info>
  <brief_title>A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors</brief_title>
  <official_title>An Open-Label, Multiple Ascending Dose (MAD) Study of the Selective BRAF Inhibitor RO5212054 (PLX3603) to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With BRAF V600-Mutated Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, multi-center study will evaluate the safety, tolerability, and
      pharmacokinetics of RO5212054 [PLX3603] in participants with BRAF V600-mutated advanced solid
      tumors. Cohorts of participants will receive escalating oral doses of RO5212054. Anticipated
      time on study treatment is until disease progression or unacceptable toxicity occurs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2010</start_date>
  <completion_date type="Actual">May 2, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Dose Limiting Toxicity</measure>
    <time_frame>Baseline up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Tolerated Dose of RO5212054</measure>
    <time_frame>Baseline up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration of RO5212054</measure>
    <time_frame>Baseline up to cycle 10 (cycle length: 21 days) (detailed timeframe is given in description)</time_frame>
    <description>Detailed timeframe:
Pre-dose (0 hour [hr]): Day 1 of Cycles 1-10; Days 4, 8, 15 of Cycle 1. Post-dose: 1, 2, 4, 8, 12, 24 hr on Day 1 Cycle 1; Between 2-4 hr (1 sample) on Day 8 Cycle 1 and Day 1 Cycles 2-9; 1, 2, 4, 8, Between 10-12 hr (1 sample), 24 hr on Day 15 Cycle 1 (cycle length: 21 days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration of RO5212054</measure>
    <time_frame>Baseline up to cycle 10 (cycle length: 21 days) (detailed timeframe is given in description)</time_frame>
    <description>Detailed timeframe:
Pre-dose (0 hr): Day 1 of Cycles 1-10; Days 4, 8, 15 of Cycle 1. Post-dose: 1, 2, 4, 8, 12, 24 hr on Day 1 Cycle 1; Between 2-4 hr (1 sample) on Day 8 Cycle 1 and Day 1 Cycles 2-9; 1, 2, 4, 8, Between 10-12 hr (1 sample), 24 hr on Day 15 Cycle 1 (cycle length: 21 days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Plasma Concentration-Time Curve of RO5212054</measure>
    <time_frame>Baseline up to cycle 10 (cycle length: 21 days) (detailed timeframe is given in description)</time_frame>
    <description>Detailed timeframe:
Pre-dose (0 hr): Day 1 of Cycles 1-10; Days 4, 8, 15 of Cycle 1. Post-dose: 1, 2, 4, 8, 12, 24 hr on Day 1 Cycle 1; Between 2-4 hr (1 sample) on Day 8 Cycle 1 and Day 1 Cycles 2-9; 1, 2, 4, 8, Between 10-12 hr (1 sample), 24 hr on Day 15 Cycle 1 (cycle length: 21 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Baseline up to approximately 7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>RO5212054: Continuous Dosing Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO5212054 in escalating dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO5212054: New Formulation (F05) Bridging Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO5212054 as a single dose of new formulation (F05-150 mg film-coated tablet with different ratios of ingredients than F03 to increase bioavailability) and a single dose of current clinical Formulation (F03-150 mg film-coated tablet) in a cross-over manner. Participants will be alternately assigned to receive either F05 or F03 as their first dose, followed by the opposite Formulation as their second dose. Dose of RO5212054 will be decided based on the results of continuous dosing cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5212054</intervention_name>
    <description>Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.</description>
    <arm_group_label>RO5212054: Continuous Dosing Cohort</arm_group_label>
    <arm_group_label>RO5212054: New Formulation (F05) Bridging Cohort</arm_group_label>
    <other_name>PLX3603</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced solid tumor

          -  Dose-escalation phase: Histologically confirmed, newly diagnosed or relapsed/
             refractory unresectable American Joint Committee on Cancer (AJCC) Stage IIIC or IV
             disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Adequate liver, renal and bone marrow function

        Exclusion Criteria:

          -  Participants for whom standard therapy exists and is considered appropriate by the
             investigator

          -  Prior treatment with an inhibitor of BRAF (sorafenib allowed)

          -  Active Central nervous system (CNS) lesions, or history of or known carcinomatous
             meningitis

          -  Treatment with any chemotherapy, radiotherapy, immunotherapy or investigational agent
             within 28 days prior to first dose of study drug

          -  Anticipated or ongoing anti-cancer therapies other than those administered in this
             study

          -  Serious cardiovascular illness within the 6 months prior to study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital; Oncology</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital; Medical Oncology</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital; Hematology and Medical Oncology</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Onkologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

